Champions Oncology

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript

HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2024, ended January 31, 2024. Third Quarter and Recent Highlights: Third quarter revenue of $12.0 million, a decline of 6% Gross margin declined to 35% College of American Pathologists (CAP) has awarded accreditation to US-based laboratory Ronnie Morris, CEO of Champions, commented, "As discussed over the course of the year, we're navigating through a challenging economic environment, specifically in the biotech sector, that began approximately one year ago.

Champions Oncology Reports Quarterly Revenue of $12.0 Million

HACKENSACK, NJ / ACCESSWIRE / March 7, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced that the College of American Pathologists (CAP) has awarded accreditation to its US-based laboratory. This achievement of CAP accreditation continues to strengthen Champions Oncology's reputation as a high-quality, state of the art laboratory providing the highest standards of excellence in histology and immunohistochemistry services.

Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation

HACKENSACK, NJ / ACCESSWIRE / March 6, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2024, on Tuesday, March 12, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024

Champions Oncology, Inc. (NASDAQ:CSBR ) Q2 2024 Earnings Conference Call December 12, 2023 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Operator Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2024 Earnings Call.

Champions Oncology, Inc. (CSBR) Q2 2024 Earnings Call Transcript

HACKENSACK, NJ / ACCESSWIRE / December 12, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2024, ended October 31, 2023. Second Quarter and Recent Highlights: Second quarter revenue of $11.6 million, a decline of 19% Revised fiscal year 2024 revenue guidance to be generally in-line with last year's results Strong quarterly bookings European lab received ISO accreditation and ATS certification Hired Brady Davis as President to develop new strategic initiatives Ronnie Morris, CEO of Champions, commented, "As discussed during our first quarter earnings call, we're navigating through a challenging economic environment, specifically in the biotech sector, that began approximately one year ago.

Champions Oncology Reports Quarterly Revenue of $11.6 Million

HACKENSACK, NJ / ACCESSWIRE / December 4, 2023 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2023, on Tuesday, December 12, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023

HACKENSACK, NJ / ACCESSWIRE / November 2, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced its European research operations site in Bresso, Italy, received ISO-9001:2015 laboratory accreditation from the Bureau Veritas S.p.A. and ATS certification from the Lombardy Region.

Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification

HACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth. "We are thrilled to have Brady join the already incredibly talented team here at Champions Oncology.

Champions Oncology Announces the Addition of Brady Davis as President

Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2024 Earnings Conference Call September 13, 2023 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Matt Hewitt - Craig-Hallum David Baron - Baron Capital Operator Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2024 Earnings Call.

Champions Oncology, Inc. (CSBR) Q1 2024 Earnings Call Transcript

HACKENSACK, NJ / ACCESSWIRE / September 13, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2024, ended July 31, 2023. First Quarter and Recent Highlights: First quarter revenue of $12.6 million, a decline of 9% Strong quarterly bookings Hosting Scientific Symposium in Boston, MA on September 26th Ronnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, the downturn in the economy, and specifically the biotech sector, was going to weigh on the Company into the start of our new fiscal year.

Champions Oncology Reports Quarterly Revenue of $12.6 Million

HACKENSACK, NJ / ACCESSWIRE / September 11, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2023, on Wednesday, September 13, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 13, 2023

HACKENSACK, NJ / ACCESSWIRE / August 22, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, kicks-off its annual series of events by hosting a scientific symposium at the Museum of Science, in Boston, Massachusetts on September 26th. This year's event, titled "Uncovering Integrative Approaches for Oncology Drug Development" will focus on how the integrated use of clinically relevant patient-derived models, multi-omics analytics, and high complexity phenotypical assays are impacting the entire drug development continuum across multiple therapeutic modalities.

Champions Oncology Aannounces Remarkable Lineup of Speakers at Its Translational Oncology Symposium in Boston in September 2023

HACKENSACK, NJ / ACCESSWIRE / August 1, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions, today announced an agreement to adopt BioVolume's leading 3D imaging and thermal technology as their primary means of capturing efficacy results. Through this multi-year agreement Champions Oncology will incorporate BioVolume's cutting-edge thermal and 3D imaging platform into its broad portfolio of in vivo preclinical offerings.

Champions Oncology Announces a Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies

Champions Oncology, Inc. (NASDAQ:CSBR ) Q4 2023 Earnings Conference Call July 24, 2023 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Scott Henry - ROTH Capital Operator Greetings, and welcome to Champions Oncology's Fourth Quarter and Fiscal Year-End 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.

Champions Oncology, Inc. (CSBR) Q4 2023 Earnings Call Transcript

Record Annual Revenue of $53.9 Million HACKENSACK, NJ / ACCESSWIRE / July 24, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2023. Fourth Quarter and Fiscal Year 2023 Financial and Recent Business Highlights: Fourth quarter revenue increased 2% to $13.1 million Record annual revenue of $53.9 million, an increase of 10% year-over-year Year-over-year fourth quarter and annual bookings increase of 15% Announced the formation of our wholly owned bio-tech subsidiary, Corellia AI, to develop novel therapeutics Ronnie Morris, CEO of Champions, commented, "Overall we had another year of business expansion, developing our platforms and investing in our drug discovery efforts.

Champions Oncology Reports Quarterly Revenue of $13.1 Million

HACKENSACK, NJ / ACCESSWIRE / July 20, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter and year ended April 30, 2023, on Monday, July 24, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 24, 2023

HACKENSACK, NJ / ACCESSWIRE / April 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled research organization that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic (PPMO) integration, announced the launch of its therapeutic discovery and development platform into a wholly owned subsidiary named Corellia AI (Corellia). Corellia launches out of Champions Oncology with a team of world class scientists advancing a robust pipeline of therapeutic programs and a unique discovery and development platform.

Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development

HACKENSACK, NJ / ACCESSWIRE / April 5, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $5 million of its common stock through April 30, 2024 pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. Ronnie Morris, CEO of Champions commented, "We are committed to strategically deploying capital to drive long-term value for stockholders.

Champions Oncology Announces $5M Stock Repurchase Program

Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2023 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Matthew Hewitt - Craig-Hallum Operator Good day, everyone, and welcome to the Champions Oncology Third Quarter Fiscal Year 2023 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Dr. Ronnie Morris, Chief Executive Officer of Champions Oncology.

Champions Oncology, Inc. (CSBR) Q3 2023 Earnings Call Transcript

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200% and 2.26%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates

HACKENSACK, NJ / ACCESSWIRE / March 15, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2023, ended January 31, 2023. Third Quarter and Recent Highlights: Record quarterly bookings Quarterly revenue of $12.8 million Adjusted EBITDA loss of $1.6 million, driven by a $1 million increase in R&D for our target discovery program Commenced in-vivo efficacy testing for therapeutic hits on lead programs Ronnie Morris, CEO of Champions, commented, "Our third quarter results were weaker than we've been accustomed to delivering, impacted primarily by the macro-economic environment.

Champions Oncology Reports Quarterly Revenue of $12.8 Million

HACKENSACK, NJ / ACCESSWIRE / March 13, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2023, on Wednesday, March 15, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023

CSBR runs a PDX bank. PDXs are mice models of human derived tumors. The company offers services to bio and pharma companies in pre clinical treatment testing. Its test have high predictive power for human results, without the associated cost.

Champions Oncology Trades At A Sufficient Discount To R&D Capacity

Champions Oncology, Inc. (NASDAQ:CSBR ) Q2 2023 Results Conference Call December 13, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Scott Henry - ROTH Capital Operator Good day, ladies and gentlemen, and welcome to the Champions Oncology Second Quarter Fiscal Year 2023 Earnings Call. At this time, all participants have been placed on a listen-only mode and the floor will be opened for you questions and comments after the presentation.

News for Champions Oncology Stock (CSBR)